Randomized phase III trial of trastuzumab monotherapy followed by trastuzumab plus docetaxel versus trastuzumab plus docetaxel as first-line therapy in patients with HER2-positive metastatic breast cancer: the JO17360 Trial Group

✍ Scribed by Kenichi Inoue; Kazuhiko Nakagami; Mitsuhiro Mizutani; Yasuo Hozumi; Yasuhiro Fujiwara; Norikazu Masuda; Fumine Tsukamoto; Mitsue Saito; Shigeto Miura; Kenji Eguchi; Tetsu Shinkai; Masashi Ando; Toru Watanabe; Noriyuki Masuda; Yasuo Ohashi; Muneaki Sano; Shinzaburo Noguchi

• Publisher: Springer US
• Year: 2009
• Tongue: English
• Weight: 368 KB
• Volume: 119
• Category: Article
• ISSN: 0167-6806
• DOI: 10.1007/s10549-009-0498-7